This study set out to examine the vasomotor effects of the opioid-like peptide nociceptin on knee joint capsular blood flow using urethane anaesthetised rats. Topical application of nociceptin (10 
INTRODUCTION
The opioid system has long been associated with chronic pain management, but there is increasing evidence to suggest that classic opioid agonists have the potential to modulate inflammatory changes in peripheral tissues. Morphine, for example, has been shown to reduce oedema formation in the rat paw and trachea (20, 22, 33) as well as being able to reduce knee joint plasma extravasation in response to capsaicin treatment (17) . Indeed, a growing body of evidence seems to suggest that opioid agonists can successfully attenuate the severity of experimentally-induced arthritis when administered either locally to the affected joint or systemically (6, 24, 41) . The mechanism by which opioids exert their anti-arthritic effects is still unclear, but this supplementary attribute could have major therapeutic implications.
Three classes of opioid receptor (termed µ, δ and κ) were originally described based on extensive pharmacological and localisation criteria. Morphine, for example, acts via the µ-opioid receptor while the endogenous opioid peptide dynorphin A shows a high affinity for the κ-opioid receptor type. In the early 1990s, a number of investigators successfully cloned the receptor genes which encode for the µ-opioid receptor (39), δ-opioid receptor (12) , and the κ-opioid receptor (25) . Arising from these receptor cloning studies emerged a novel receptor which exhibited about 65% homology to the δ-opioid receptor but which did not bind any of the known endogenous opioids (10, 31, 40) . With no known agonist, the receptor was termed the opioid-like orphan receptor (ORL-1). The endogenous ligand for the ORL-1 receptor was later found to be a heptadecapeptide called nociceptin (also known as orphanin FQ) whose amino acid sequence is similar to that of dynorphin (30, 34) . Immunolocalisation studies have identified nociceptin in the central nervous system (32, 35, 38) where it acts as a modulator of pain, long term potentiation, and locomotor activity (11, 16) . More recently, nociceptin has also been identified in a number of peripheral tissues including rat ankle joints (1) . Information regarding the physiological function of nociceptin in the periphery is scarce, but a few studies have found that nociceptin can influence cardiovascular regulation as well as modulate nociception. In vivo studies in rats revealed that systemic nociceptin administration produces transient hypotension and bradycardia (5, 9, 15) . These cardiovascular effects seem to be autonomically controlled since sympathetic blockade by guanethidine treatment and bilateral cervical vagotomy altered the level of bradycardia and hypotension in nociceptin treated animals (15) . Conflicting results were reported by Arndt et al. (4) who found in alert sheep that nociceptin caused an increase in systemic blood pressure and heart rate. Pre-treatment of the animals with the non-specific α-adrenoceptor antagonist phenoxybenzamine abrogated these effects suggesting once again that the cardiovascular changes produced by nociceptin were sympathetically dependent.
In normal rat knee joints, nociceptin has been found to cause a hypersensitisation of articular afferents demonstrating the existence of functional ORL-1 receptors in joint tissues (27, 29) . The observation that nociceptin-containing nerves occur in close proximity to articular blood vessels (1) implies that in addition to its nociceptive properties, nociceptin may also be involved in joint vasomotor control mechanisms and neurogenic inflammation. Although nociceptin does not itself affect synovial plasma extravasation, it is able to inhibit articular vascular leakiness in response to 5-hydroxytryptamine (18) . The present study set out to investigate whether peripherally administered nociceptin could alter joint capsular blood flow and to see whether sympathetic nerve fibres are involved in the vasomotor changes. To fully characterise the ORL-1 receptor in the rat knee joint, nociceptin dose-response curves were repeated in the presence of the recently described ORL-1 specific receptor antagonist [Phe 
MATERIALS & METHODS
Experiments were performed on 65 male Wistar rats (215-382g) deeply anaesthetised by intraperitoneal injection of urethane (1.5g/kg) and depth of anaesthesia was confirmed by an absence of the pedal withdrawal reflex. The skin covering the joint was shaved and the rat was placed supine on a thermostatically controlled heating pad (Fine Science Tools Inc., North
Vancouver, Canada). Core body temperature was maintained in the 36 -37°C range as measured by a rectally inserted thermosensitive probe.
Surgical procedures
All surgical and experimental procedures had received prior approval from the University of Calgary Animal Care Committee which is in accordance with the Canadian Council for Animal Care guidelines.
A longitudinal incision was made in the neck of the rat and the exposed trachea cannulated to allow unrestricted breathing. Two animals experienced respiratory irregularities and were therefore artificially ventilated with 100% O 2 . The left carotid artery was then isolated and cannulated with a heparinised saline-filled cannula (1.0mm outer diameter polyethylene tubing; Portex, Kent, UK). The carotid cannula was connected to a pressure transducer (Stoelting Co., Illinois, USA) which allowed mean arterial pressure to be recorded on a blood pressure 6 monitor (World Precision Instruments, Florida, USA). An ellipse of skin overlying the knee joint was excised and the fascia covering the joint was removed to expose the joint capsule (synovium and associated fibrous tissues -see Figure 1A ). To prevent desiccation of articular structures, warmed (37°C) physiological saline (0.9% NaCl) was regularly superfused over the surface of the knee which in itself has no measurable effect on joint blood flow (26) . While observing the knee under a dissecting microscope, black cloth was carefully placed around the circumference of the joint to cloak non-articular structures thereby delimiting the field of view to the joint.
Blood flow assessment
Relative changes in knee joint perfusion were ascertained by a laser Doppler imager (Moor Instruments Ltd., Axminster, UK) using previously described protocols which have been 
Studies to test sympathetic involvement
It has been suggested that the cardiovascular effects of nociceptin in some species are achieved via the activation of the sympathetic nervous system (4). To investigate whether the nociceptin-induced blood flow changes described here were sympathetically mediated, two sets of experiments were carried out. The first involved treating a group of rats with guanethidine (50mg/kg/day i.p. for 3 consecutive days) which results in supramaximal blockade of sympathetic neurotransmission rendering them functionally inert at the time of blood flow assessment. This treatment regimen should not be confused with chronic guanethidine treatment which results in general sympatholysis. A dose-response curve using nociceptin was generated in 8 the guanethidine-treated animals. In a separate group of rats, postjunctional α-adrenoceptors were pharmacologically blocked by administering the non-specific α-adrenoceptor antagonist phentolamine (10 -6 mol topical) for 6min prior to and concurrently with each dose of nociceptin.
To test the effectiveness of guanethidine blockade and phentolamine antagonism on sympathetic activity, additional experiments were performed in a subset of treated animals in which the knee joint sympathetic nerve supply was electrically stimulated. Here, the saphenous nerve was isolated in the inguineal region of the hindlimb and then centrally transected. The cut nerve end was placed over silver bipolar electrodes and electrically stimulated by a Harvard Stimulator (Model 6012; Harvard Apparatus, Canada) with the stimulating parameters set at delay 1ms, pulse width 1ms, voltage 15V and frequency 30Hz. This stimulation regimen has previously been shown to elicit a potent sympathetically-mediated vasoconstriction of rat knee joint blood vessels (28) .
Capsaicin treatment
Destruction of unmyelinated knee joint afferent nerves was produced by intraarticular injection of 1% capsaicin (vehicle consisting of 5% ethanol, 5% cremophor and physiological saline). Rats were deeply anaesthetised by intraperitoneal injection of diazepam (2.5mg/kg) and intramuscular injection of Hypnorm (0.2ml/kg) and the right knee joint was shaved and swabbed with alcohol. 0.2ml of the capsaicin solution was injected into the joint cavity with 0.1ml being introduced into the posterior and 0.1ml into the anterior compartments of the joint. Animals were allowed to recover for 1 week which has been shown to be the optimal time point for almost complete destruction of rat knee joint unmyelinated nerve fibres (13) . As such, I am confident that unmyelinated and thinly myelinated nerve fibres were destroyed in this study.
Laser Doppler image analysis and statistics
Each Doppler image of the knee joint was analysed using Moor Image Processor software (Moor instruments Ltd., Axminster, UK). A region of interest analysis area was selected which encompassed the knee joint and the mean flux for the knee was calculated and reported in arbitrary perfusion units (PU). Blood flow changes in response to drug administration were expressed as a percent change in PU between the test scan and the control scan taken immediately prior to drug administration. The relative potency of nociceptin alone and in the presence of the antagonists was determined by ED 50 comparisons. The ED 50 s were calculated from linear regression analyses of the dose-response curves using GraphPad Prism software (GraphPad Software, San Diego, USA). All data were tested for normality using the Kolmogorov-Smirnov test with GraphPad Prism software. All data were found to be not significantly different from a Gaussian distribution (P>0.10) and were therefore analysed using 
RESULTS

Effects of nociceptin on knee joint blood flow
Application of nociceptin onto the surface of rat knee joints was found to cause a progressive reduction in articular blood flow (Figure 1 ). However, this vasoconstrictor response (Table 1) . Figure 3D ). A one factor ANOVA confirmed that this hyperaemic response was statistically significant (P<0.05; n = 10).
Latent vasodilator effect of nociceptin
Effects of guanethidine or phentolamine treatment
In control knees, electrical stimulation of the saphenous nerve produced a 47.2 ± 4.59% fall in perfusion (Figure 4 ). This vasoconstrictor response was significantly inhibited by either guanethidine treatment or phentolamine co-administration (P<0.05 one-factor ANOVA; n = 5 -8) clearly showing that these treatments block sympathetic activity in the joint.
As shown in Figure 5 , guanethidine treatment caused a significant inhibition of nociceptin-induced vasoconstriction in the rat knee (P<0.05 two factor ANOVA; n = 15 -16).
Similarly, antagonism of smooth muscle α-adrenoceptors by co-administration of the α-adrenergic antagonist phentolamine also attenuated the constrictor capacity of nociceptin (P<0.05). Mean arterial pressure was unaffected by drug application in these experiments confirming that blood flow changes were due to local vascular responses and not a consequence of blood pressure fluctuations (Table 1) .
DISCUSSION
The identification of the opioid-like peptide nociceptin has yielded a plethora of information regarding the role of this neuropeptide in the control of pain. Less known is the ability of nociceptin to modulate other physiological processes such as vasoregulation. The present study found that peripherally administered nociceptin produced a reduction in rat knee joint perfusion which could be inhibited by the specific ORL-1 receptor antagonist [Phe 1 -(CH 2 -NH)-Gly 2 ] Nociceptin(1-13)-NH 2 as well as the non-specific opioid antagonist naloxone. It should be noted that neither antagonist alone nor the vehicle in which all drugs were dissolved (0.9% saline) had any effect on synovial blood flow. The vasoconstrictor effect of nociceptin is somewhat unexpected since nociceptin has mainly been shown to cause systemic hypotension and peripheral vascular relaxation in a number of species including rats (5, 9, 15) . In these studies, however, nociceptin was administered systemically and as such may be exerting its inhibitory effects on the cardiovascular system via a central mechanism or by direct activation of 13 the heart. Conversely in the experiments described here, nociceptin was localised to the periphery as evidenced by the lack of any effect of the neuropeptide on mean arterial blood pressure (see Table 1 ). Hence, the vasoconstrictor response of nociceptin in the rat knee is purely a microcirculatory effect which is independent of cardiac stimulation or baroreceptor reflexes.
The shown that naloxone attenuates a pressor and tachycardia response to nociceptin. Interestingly, in both of these studies as well as the present investigation, nociceptin was producing atypical effects ie. analgesia instead of hyperalgesia, hypertension rather than hypotension, tachycardia as opposed to bradycardia, and vasoconstriction instead of vasodilatation. Thus, nociceptin appears to be able to exert distinct and conflicting actions in vivo of which one set of responses appears to be naloxone sensitive. Some of the peripheral effects of nociceptin have been attributed to the ability of the peptide to modulate neurotransmitter release at a prejunctional level from sensory and sympathetic nerves (for review see 14) . The present investigation, therefore, tested whether the vasoconstrictor effects of nociceptin were sympathetically mediated. As evidenced in the nerve stimulation experiments, supramaximal sympathetic blockade was achieved by systemic guanethidine pre-treatment while 10 -6 mol phentolamine was sufficient in producing α-adrenoceptor antagonism. A slight vasodilatation was observed during nerve stimulation in guanethidine treated rats (see Figure 4 ) and this effect was probably due to a small population of joint afferents being stimulated. Some of these sensory nerves contain inflammatory peptides such as substance P which will be released into the joint resulting in the reported mild vasodilatation. Both guanethidine treatment and phentolamine co-administration significantly inhibited nociceptin-induced vasoconstriction in the knee. This finding supports the idea that nociceptin is acting prejunctionally on sympathetic nerve endings in the joint to cause the secondary release of noradrenaline which in turn is responsible for the synovial vasoconstriction.
In One possible explanation for the increased perfusion of the joint could be due to nociceptin causing secondary release of pro-inflammatory peptides into the knee. Hyperalgesia caused by peripherally applied nociceptin appears to be dependent upon substance P release from unmyelinated afferent nerve endings (21, 27) and this same mechanism could be responsible for the dilator activity of nociceptin in joints. This possibility was tested by treating a group of rats with intraarticular injection of 1% capsaicin which has been shown to destroy unmyelinated nerve endings in the rat knee at one week following treatment (13) . In these capsaicin treated rats, co-administration of [Phe 1 -(CH 2 -NH)-Gly 2 ] Nociceptin(1-13)-NH 2 and 10 -8 mol nociceptin still produced a potent vasodilatation indicating that nociceptin is exerting its dilator effects directly on the vascular smooth muscle and not via secondary release of neurogenically-derived inflammatory mediators such as substance P into the joint. It could be argued that nociceptin is causing the release of endothelially-derived factors such as nitric oxide, however, an abundance of evidence contests that nociceptin does not interact with the vascular endothelium to alter blood vessel tone (3, 8) .
The model system employed in this study, while not purely physiological, does extend the opportunity to test drug responses and thereby deduce the physiological activity of the endogenous receptors. The physiological significance of the presented findings is complicated by the fact that endogenous nociceptin levels in the rat knee are not known. Circulating nociceptin 16 in humans is thought to be as low as 10 pg/ml (7) which when applied to the present investigation would suggest that nociceptin plays only a minor role in the basal modulation of joint blood flow. However, the concentration of the peptide in the tissues is likely to be considerably higher than circulating levels indicating that nociceptin may still contribute to the physiological control of joint perfusion. Of greater importance is the role of nociceptin during inflammation where levels of the peptide are known to increase (2) . Here, accumulation of nociceptin in the joint would attenuate synovial hyperaemia and potentially reduce joint inflammation. As peptide levels continue to rise, however, nociceptin would eventually become pro-inflammatory as its dilator characteristics are suddenly invoked. More information regarding nociceptin levels in normal and inflamed joints is therefore required to provide a clearer appreciation of the involvement of this neuropeptide in joint homeostasis and pathology.
As alluded to earlier, nociceptin can produce parallel but opposing physiological responses (18, 27, 29, 37) . A dual action of nociceptin has been described here in the rat knee where high dose nociceptin causes a transient capsular hyperaemia which is not neurogenically mediated. This dilator response is succeeded by a more prolonged vasoconstrictor response which is sympathetically mediated. Further investigation into the complex function of nociceptin and its diverse effects in vivo may yield meaningful information regarding the role of this peptide in the control of joint pain and inflammation. 
